加载中
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
收盘时
US$1.04
−US$0.03 · -2.80%
盘后
US$1.04
US$0.00 · 0.00%
10月12日 19:54 ET
盘中时间采用ET。市场数据可能有所延迟。
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
日内区间
当前US$1.04
52周区间
当前US$1.04
盘中时间采用ET。市场数据可能有所延迟。
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
日内区间
当前US$1.04
52周区间
当前US$1.04
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 9.1万 USD | 10.6万 USD | — | — |
| 毛利 | — | −9.1万 USD | −10.6万 USD | — | — |
| 研究与开发 | 628.3万 USD | 663万 USD | 572.4万 USD | 773.6万 USD | 615.3万 USD |
| 销售、一般及管理费用 | 824.7万 USD | 499.5万 USD | 413.1万 USD | 558.1万 USD | 541万 USD |
| 营业费用 | 1474.3万 USD | 1153.4万 USD | 974.9万 USD | 1328.1万 USD | 1135.7万 USD |
| 利息收入 | 128.5万 USD | 18.2万 USD | 22.8万 USD | 5.4万 USD | 4.4万 USD |
| 折旧和摊销 | 4.7万 USD | 9.1万 USD | 10.6万 USD | 10.2万 USD | 7.6万 USD |
| 营业利润 | −1474.3万 USD | −1162.5万 USD | −985.5万 USD | −1328.1万 USD | −1135.7万 USD |
| 净利润 | −1314.2万 USD | −1144.3万 USD | −1074万 USD | −1316.8万 USD | −1131.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.00
上涨空间 284.62%评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI314.37万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF111.96万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC23.41万0.02%13.17亿 USD0.60%US$181.66-0.73%
Invesco NASDAQ Future Gen 200 ETFQQQS8.62万0.38%2275.83万 USD0.20%US$41.414-1.73%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
